[Immunotherapy with decaris in the early stages of breast cancer].
A randomized clinical study of adjuvant immunotherapy with decaris was carried out in patients with early breast cancer. 92 patients with stages I and IIA tumors (T1,2N0M0) received 300 mg decaris weekly (150 mg for 2 successive days) 2 weeks after radical mastectomy (Patey) used as a sole preventive therapy. The short (1 month) (group I), the medium (3 months) (group 2) and the long-term intermittent (three 3 month courses during 15 months) (group 3) modalities were compared. The prolonged intermittent course of decaris administration proved superior since it assured improvement in immunity and longer relapse-free survival, and lacked apparent toxicity. Five-year survival in all decaris treated patients was 93.8%, while five-year relapse-free course in group 3 was registered in 96.9%.
Polevaia
E B
EB
Derevnina
N A
NA
Trubchaninova
L P
LP
Veskova
T K
TK
D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007978:Levamisole / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011897:Random Allocation; D012397:Rosette Formation; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors
D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007978:Levamisole
Immunoterapiia dekarisom pri nachal'nykh stadiiakh raka molochnoĭ zhelezy.